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Abstract
Background: Doxorubicin is an effective breast cancer drug but is hampered by a severe, dose-dependent
toxicity. Concomitant administration of doxorubicin and another cancer drug may be able to sensitize tumor cells
to the cytotoxicity of doxorubicin and lowers the therapeutic dosage. In this study, we examined the combined
effect of low-dose doxorubicin and siRNA inhibition of telomerase on breast cancer cells. We found that when
used individually, both treatments were rapid and potent apoptosis inducers; and when the two treatments were
combined, we observed an enhanced and sustained apoptosis induction in breast cancer cells.
Methods:  siRNA targeting the mRNA of the protein component of telomerase, the telomerase reverse
transcriptase (hTERT), was transfected into two breast cancer cell lines. The siRNA inhibition was confirmed by
RT-PCR and western blot on hTERT mRNA and protein levels, respectively, and by measuring the activity level
of telomerase using the TRAP assay. The effect of the hTERT siRNA on the tumorigenicity of the breast cancer
cells was also studied in vivo by injection of the siRNA-transfected breast cancer cells into nude mice.
The effects on cell viability, apoptosis and senescence of cells treated with hTERT siRNA, doxorubicin, and the
combined treatment of doxorubicin and hTERT siRNA, were examined in vitro by MTT assay, FACS and SA-β-
galactosidase staining.
Results: The hTERT siRNA effectively knocked down the mRNA and protein levels of hTERT, and reduced the
telomerase activity to 30% of the untreated control. In vivo, the tumors induced by the hTERT siRNA-transfected
cells were of reduced sizes, indicating that the hTERT siRNA also reduced the tumorigenic potential of the breast
cancer cells. The siRNA treatment reduced cell viability by 50% in breast cancer cells within two days after
transfection, while 0.5 μM doxorubicin treatment had a comparable effect but with a slower kinetics. The
combination of hTERT siRNA and 0.5 μM doxorubicin killed twice as many cancer cells, showing a cumulative
effect of the two treatments.
Conclusion: The study demonstrated the potential of telomerase inhibition as an effective treatment for breast
cancer. When used in conjunction to doxorubicin, it could potentiate the cytotoxic effect of the drug to breast
cancer cells.
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Background
Breast cancer is the most common cancer diagnosed in
American women and is the second leading cause of can-
cer-related deaths [1]. About 200,000 new cases are diag-
nosed each year in the United States [2]. Chemotherapy is
frequently used to relieve symptoms in advanced breast
cancer patients and to reduce the risk of recurrence in
patients with localized breast cancer. Doxorubicin (trade
name Adriamycin) is one of the most commonly used
drugs to treat breast cancer [1,3]. Monotherapy with dox-
orubicin has a good response rate of 10–50% [1], and
doxorubicin-containing combination therapies usually
result in better survival rate [4,5]. Other than for breast
cancer treatment, doxorubicin is also used to treat a wide
variety of solid tumors and hematological malignancies
[6].
The clinical utility of doxorubicin and other anthracy-
clines are limited by their toxicity. Among the side effects
are myelosuppression, acute nausea and vomiting, alo-
pecia and cardiotoxicity related to cumulative dose [6,7].
Advances have been made in drug formulation and sched-
ules of chemotherapy to better the safety profile and effi-
cacy of doxorubicin. Liposomal doxorubicin
formulations had been developed to counter the cardio-
toxicity and increase the therapeutic index of the conven-
tional anthracyclines [7]. Shortening the period between
treatments in chemotherapy schedules also seems to
increase the drug's effectiveness [1,2].
Doxorubicin induces single and double strand breaks in
DNA mediated by topoisomerase II [8]. The ubiquitous
expression of topoisomerases contributes to the non-
selective targeting of doxorubicin, and is a major reason
for its toxicity [6]. The toxicity of doxorubicin can be
reduced if it is used in conjunction with another, more
tumor-specific treatment in order to reduce the dosage.
Telomerase plays a vital role in tumor proliferation. It syn-
thesizes the telomeric repeats at the ends of chromosomes
and replaces the progressively lost end sequences during
each cell cycle, allowing cells to escape mortality and con-
tinue to proliferate. Telomerase is relatively specifically
expressed in many tumor tissues, including breast cancer,
and is repressed in most normal somatic tissues [9-12].
The tumor-specific expression of telomerase has made it a
highly attractive cancer therapy target [13].
One method of specific inhibition of telomerase is
through RNA interference (RNAi). Since its discovery,
RNAi has been shown as a potent post-transcriptional
gene silencing mechanism [14,15]. Introduction of small
interfering RNAs (siRNAs) can mediate the specific degra-
dation of the mRNA, whose sequence is contained in the
siRNAs. The strong and specific suppression of gene
expression by RNAi is currently being evaluated as a
potentially useful method for developing gene-silencing
therapies for cancer [16,17]. There have been reports
which demonstrated that RNAi against telomerase reverse
transcriptase (hTERT), the protein component of telomer-
ase, could successfully inhibit telomerase activity in sev-
eral cancer cell lines. [18-23].
In this study, we hypothesized that a combination treat-
ment of doxorubicin and hTERT siRNA could sensitize
tumor cells to doxorubicin and thus enhance its cytotox-
icity. We first characterized the effect of our hTERT siRNA
in promoting breast cancer cells apoptosis in vitro and in
vivo. We then compared the effects of hTERT siRNA, low
dose doxorubicin and the combined treatment of the two
to see if a cumulative effect would be observed when the
two treatments were combined.
Methods
siRNA preparation
The siRNA sequences were designed by a commercial soft-
ware (Applied Biosystems/Ambion, Austin, TX). For
hTERT, the siRNA sense sequence is 5'-UGAUUUCUUG-
UUGGUGACAdTdT-3', and the anti-sense sequence is 5'-
UGUCACCAACAAGAAAUCAdTdT-3'. The negative con-
trol siRNA sense sequence is 5'-GGCCU-
CAGCUGCGCGACGCdTdT-3', and the antisense
sequence is 5'-GCGUCGCGCAGCUGGGCCAdTdT-3'.
The selected sequences were submitted to BLAST http://
www.ncbi.nlm.nih.gov/blast/ to ensure that the selected
gene was targeted specifically. The siRNAs were synthe-
sized and sequenced by Guangzhou RiboBio Co., Ltd,
Ghuangzhou, China.
Cell culture
The breast cancer cell lines, MCF-7 and MDA-MB-453
(both purchased from American Type Culture Collection,
Manassas, VA), were grown in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin and 100 μg/ml strep-
tomycin at 37°C and 5% CO2. All culture medium and
supplements were purchased from Invitrogen, Carlsbad,
CA.
hTERT siRNA transfection
MCF-7 cells (2 × 105 cells per well) and MDA-MB-453
cells (3 × 105 cells per well) were plated in 6-well plates
and allowed to grow overnight. 200 pmol siRNA and 5 μl
Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA) were
diluted in OPTI-MEM (Invitrogen, Carlsbad, CA) to a
total volume of 250 μl. The diluted siRNA and Lipo-
fectamine™2000 were mixed and incubated at ambient
temperature for 20 minutes. The cells were washed with
serum-free DMEM medium, and then the diluted siRNA
mix was added to the 6-well plates for 6 hours, after which
the mix was replaced with growth medium.BMC Cancer 2009, 9:133 http://www.biomedcentral.com/1471-2407/9/133
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Reverse transcription and quantitative PCR (RT-qPCR)
Cells were collected 48 hours after siRNA transfection.
Total RNA was isolated by TRIzol Reagent (Invitrogen,
Carlsbad, CA) using the manufacturer's single-step chlo-
roform-extraction protocol. Complementary DNA was
synthesized using the First-strand cDNA synthesis kit
(Takara, Shiga, Japan). An aliquot of 1 μg of total RNA was
reverse-transcribed by MMLV transcriptase (Invitrogen,
Carlsbad, CA) using random hexamer primers according
to the manufacturer's instructions. The reaction system of
real-time PCR with dual-labeled Taqman probes was: 10
μl of 2 × Premix EX Tag TM buffer, 0.4 μl of 10 pmol/ml
of each primer, 0.8 μl of probe, 2 μl cDNA and 6.4 μl
nuclease-free distilled water. For hTERT, the sense primer
sequence is 5'-CCGTCTGCGTGAGGAGATC-3', and the
anti-sense primer sequence is 5'-TCCGGTAGAAAAA-
GAGCCTGTT-3', and the Taqman probe 5'-FAM-
GGCCAAGTTCCTGCACTGGCTGACT-TAMRA-3'. For
GAPDH, the sense primer sequence is 5'-CCAGGT-
GGTCTCCTCTGACTT-3', and the anti-sense primer
sequence is 5'-GTTGCTGTAGCCAAATTCGTTGT-3', and
the Taqman probe 5'-FAM-AACAGCGACACCCACTC-
CTCCACC-Eclipse-3'. Reaction parameters were: 95°C for
10 s, then 95°C for 5 s and 60°C for 20 s, 40 cycles. Rela-
tive gene expression of hTERT was calculated with the 2-
(ΔΔCT) method [24], using GAPDH as the reference gene.
Detection of hTERT protein expression
Cells were collected 48 hours after siRNA transfection.
After washing with pre-chilled phosphate-buffered saline
(PBS), cells were lysed in 1 ml of 1% Nonide P-40, 25 mM
Tris-HCl, 150 mM NaCl, 10 mM EDTA, pH8.0, containing
a 1:50 dilution of a protease inhibitor mixture for 30 min
on ice. hTERT protein was separated using a 5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The β-actin loading control was separated using a
10% SDS-PAGE. Proteins were electrotransferred onto a
nitrocellulose membrane and blocked for 3 hours in 3%
bovine serum albumin after the transfer. Membranes were
incubated overnight at 4°C with an hTERT primary anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA), then
washed and incubated with an alkaline phosphatase-con-
jugated secondary antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) in TBST for 2 hours. The bands were vis-
ualized using NBT/BCIP color substrate and were scanned
and analyzed.
Telomerase activity assay
Telomerase activity was determined by using a PCR-based
telomeric repeat amplification protocol (TRAP) enzyme-
linked immunosorbent assay (ELISA) kit (Roche, Man-
nheim, Germany) according to manufacturer's protocol.
In brief, MCF-7 and MDA-MB-453 cells were collected 48
hours after the siRNA transfection. The cells were washed
three times with cold PBS, homogenized in 200 μl cell
lysis buffer, and incubated on ice for 30 min. For the TRAP
reaction, 2 μl of cell extract was added to 25 μl of reaction
mixture and sterile water was added to a final volume of
50 μl. PCR was then performed as follows: prime elonga-
tion (20 min, 25°C), telomerase inactivation (5 min,
94°C), product amplification for 30 cycles (94°C for 30 s,
50°C for 30 s, 72°C for 90 s) and then balance (10 min at
72°C). 5 μl of PCR products were bound to a streptavidin-
coated 96 well plate and hybridized to a digoxigenin
(DIG)-labeled telomeric repeat specific detection probe.
The immobilized PCR products were detected with perox-
idise conjugated anti-DIG antibody. After addition of the
stop reagent, the plate was assessed on a plate reader at a
wavelength of 450 nm within 30 min.
MTT assay for cell viability
MCF-7 and MDA-MB-453 cells (2 × 104 cells/well for both
cell lines) were incubated in 96-well plates each contained
200 μl of medium. The cells were divided into six groups:
1) blank group; 2) control siRNA group; 3) hTERT siRNA
group; 4) blank and doxorubicin group; 5) control siRNA
and doxorubicin group; 6) hTERT siRNA and doxorubicin
group. Transfection of siRNAs was done the following day
as described previously. 12 hours after the siRNA transfec-
tion, the cells of the appropriate groups were treated with
doxorubicin (Zhejiang Hisun Pharmaceutical Co, Ltd,
Taizhou, China) to a final concentration of 0.5 μM. The
rate of cellular proliferation was measured every 24 hours
for 96 hours. At the end of each time point, 20 μl of 5 mg/
ml MTT (Sigma, St. Louis, MO) was added to each well.
Four hours later, 200 μl of DMSO was added to the MTT-
treated wells and the absorption at 492 nm was deter-
mined on a spectrometer. Each experimental condition
was carried out in triplicate.
Flow cytometry for cell apoptosis detection
MCF-7 cells and MDA-MB-453 cells were plated in 6-well
plates and were divided into the same six groups as in the
MTT assay. The siRNA transfection and doxorubicin treat-
ment were as before. After 48 hours, cells were collected
and washed twice with pre-chilled PBS. The cell concen-
tration was adjusted to 5 × 105~5 × 106 cells/well with 100
μl of pre-chilled binding buffer. 5 μl of Annexin V-FITC
and 5 μl of propidium iodide (PI) were added to each
sample and incubated for 10 min in the dark on ice. 400
μl of pre-chilled binding buffer was added at the end. The
cell apoptosis was determined by flow cytometry. Apopto-
sis of each group was assayed three times.
Senescence associated β-galactosidase staining
MCF-7 cells and MDA-MB-453 cells were divided into the
same six groups as in the MTT assay. The siRNA transfec-
tion and doxorubicin treatment were as before. After 48
hours, cells were rinsed three times with PBS and fixed in
2% formaldehyde, 0.2% glutaraldehyde for 5 minutes.BMC Cancer 2009, 9:133 http://www.biomedcentral.com/1471-2407/9/133
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The cells were washed again with PBS and stained over-
night at 37°C in β-galactosidase stain solution containing
1 mg/ml 5-bromo-4-chloro-3-inolyl-β-galactosidase, 40
mM citric acid/sodium phosphate (pH = 6.0), 5 mM
potassium ferrocyanide, 150 mM NaCl, and 2 mM MgCl2.
After staining, the cells were rinsed with PBS and the
stained cells were observed under a microscope. The per-
centage of β-galactosidase-positive cells was calculated by
counting 3 representative fields of at least 100 cells in each
group.
Tumor induction in nude mice with breast cancer cells 
injection
The animal study was approved by the First Affiliate Hos-
pital of Shaoxing University (Shaoxing, China). Female
BALB/c nude (nu/nu) mice were purchased from SLAC
Laboratory Animals (Shanghai, China) and were divided
into three groups with 5 mice in each group: the untreated
group, the negative siRNA group, and the hTERT siRNA
group. Six hours after siRNA transfection, cells were
trypsinized, washed with PBS, and resuspended in serum-
free DMEM to a concentration of 2 × 107 cells/ml. 2 × 106
cells (i.e., 0.1 ml of the resuspended cells) were injected
into each flank of the mice subcutaneously. The tumor
volumes were measured with a caliper every 3 days for 30
days. Tumor volume was calculated by the formula of
tumor volume (mm3) = (d2 × D)/2, where d is the short
diameter, and D is the long diameter. All measurements
were performed in a coded, blinded fashion. The experi-
ment was done with both MCF-7 and MDA-MB-453 cells.
Results
1. Down-regulation of telomerase activity in breast cancer 
cells after siRNA transfection
We initially tested three sets of siRNAs for the hTERT
knockdown. Preliminary results showed one set being
particular effective (data not shown); thus, all experi-
ments described in this report were conducted with this
siRNA (sequence see methods section).
The hTERT siRNA was transiently transfected into the
breast cancer cell lines MCF-7 and MDA-MB-453. After 48
hours, the hTERT mRNA and protein levels were quanti-
fied by real time RT-PCR and western blots, respectively.
As shown in Fig. 1A and 1B, hTERT siRNA transfection sig-
nificantly reduced the amount of hTERT mRNA. The level
of hTERT mRNA in the hTERT siRNA-treated group was
about 40% of the blank group in MCF -7 cells and about
38% in MDA-MB-453 cells. The control siRNA had no
effect on the hTERT mRNA level in either cell line. The
results between MCF-7 and MDA-MB-453 cells were not
significantly different, indicating that the effect of the
hTERT siRNA was specific. The hTERT siRNA was also suc-
cessful in knocking down hTERT protein expression. As
shown in Fig. 1C and 1D, while the β-actin internal con-
trol showed equal loading among the three groups, the
level of hTERT protein was noticeably lower in the hTERT
siRNA-treated group compared to both the blank and the
negative siRNA-treated groups, suggesting that the hTERT
siRNA treatment could effectively reduce the hTERT pro-
tein level.
The level of telomerase activity in human breast cancer
has been shown to significantly correlate with that of the
hTERT mRNA expression [25]. Consistent with this, we
found that the hTERT siRNA transfected cells showed a
70% reduction in telomerase activity, as determined by a
PCR-based telomeric repeat amplification protocol
(TRAP) ELISA (Fig. 1E and 1F)
2. hTERT siRNA inhibited cell viability in vitro and in vivo
Decreased telomerase activity is associated with arrested
cell growth; we thus sought to determine whether or not
the hTERT siRNA-induced reduction in telomerase activity
would affect cell viability in the two breast cancer cell
lines. The cells were transfected with the hTERT siRNA as
previously, and the amount of viable cells was determined
by the MTT assay every 24 hours for four days. As shown
in Fig. 2A and 2B, the hTERT siRNA significantly
decreased the percentage of viable cells in both cell lines.
The effect of the siRNA was similar in both cell lines. The
decrease was rapid: only ~63% of cells were alive after 24
hours, and only 50% of cells survived after 48 hours. The
number of surviving cells remained at about 50% from
there on and seemed to be heading into a recovery trend,
consistent with the transient nature of the siRNA transfec-
tion.
We next determined whether or not the hTERT siRNA
could negatively affect the in vivo growth of the breast can-
cer cells. We tested the ability of the hTERT siRNA to
down-regulate the tumorigenic potential of the two cancer
cells lines. Cells that were transfected with hTERT siRNA,
control siRNA or untransfected cells were injected into the
flanks of nude mice, and the volume of the tumors
induced were measured every three days for thirty days. As
shown in Fig. 2C and 2D, although all three groups of
mice developed tumors, the growth of the tumors from
the hTERT siRNA-transfected cells was significantly
slower, and the volume of tumors was much smaller, as
compared to the groups that received the untransfected
and the control siRNA-transfected cells. At the end of the
thirty days, the hTERT-siRNA transfected tumors were, on
average, about 40% the volume of the two control groups.
The volumes of tumor between the two control groups
were not different, showing the specificity of the effect of
the hTERT siRNA.BMC Cancer 2009, 9:133 http://www.biomedcentral.com/1471-2407/9/133
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Effects of hTERT-siRNA knock-down in breast cancer cells Figure 1
Effects of hTERT-siRNA knock-down in breast cancer cells. (A and B) hTERT mRNA expression levels quantified by 
RT-PCR in MCF-7 (A) and MDA-MB-453 (B) cells at 48 h after a 6 h exposure in hTERT siRNA, control siRNA, or untrans-
fected, respectively. Relative quantification of hTERT mRNA expression levels was accomplished by the Pfaffl method of 
 Data are shown as mean ± SD (error bar) of 3 experiments; *, p = 0.001, two-tailed student's t-test. (C and D) rep-
resentative western blots showing the expression of hTERT protein expression levels at 48 h after a 6 h exposure in hTERT 
siRNA (right lane; hTERT), control siRNA (middle lane; control), or untransfected (left lane; blank), respectively, in MCF-7 (C) 
and MDA-MB-453 (D) cells. β-actin was the internal loading control. (E and F) Telomerase activity levels quantified by TRAP 
assay in MCF-7 (E) and MDA-MB-453 (F) cells at 48 h after a 6 h exposure in hTERT siRNA, control siRNA, or untransfected, 
respectively. Data are shown as mean ± SD (error bar) of 3 experiments; *, p = 0.001, two-tailed student's t-test.
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3. Decrease in cell viability caused by the hTERT siRNA 
was due to increase in apoptosis
To determine whether the decrease in cell viability caused
by the hTERT siRNA was due to an increase in apoptosis
or a decrease in cell proliferation, we checked the amount
of apoptotic cells from the untransfected, control siRNA-
transfected and hTERT siRNA-transfected cells by Annexin
V-FITC and propidium iodide (PI) labeling followed by
fluorescence-activated cell sorting (FACS). 48 hours after
the siRNA transfection, both cell lines had about 20% of
the hTERT siRNA-transfected cells as apoptotic, i.e.,
Annexin V-FITC and/or PI positive, while cells in the
blank and the control siRNA groups were almost all non-
apoptotic (Fig. 3A).
4. hTERT siRNA and doxorubicin treatments combined 
could additively increased breast cancer cell apoptosis
We also determined the cytotoxicity of low-dose doxoru-
bicin alone on our cell lines. We treated both cell lines
with 0.5 μM doxorubicin and carried out the MTT assay
and FACS for apoptotic cells as were for the siRNA treated
cells. The doxorubicin concentration is low when com-
Effects of hTERT-siRNA combined with doxorubicin on the proliferation of breast cancer cells Figure 2
Effects of hTERT-siRNA combined with doxorubicin on the proliferation of breast cancer cells. The MCF-7 (A) 
and MDA-MB-453 (B) breast cancer cells were either untreated or treated with 0.5 μM doxorubicin 12 h after the siRNA 
transfection. Cell viability was measured by the MTT assay every day for 4 days. Data are shown as mean ± SD from three 
independent experiments. Panel C and D show the inhibition effect of hTERT siRNA on the tumorigenic potential of human 
breast cancer cells. 2 × 106 MCF-7 cells (C) or MDA-MB-453 cells (D) that were untreated or transfected with control siRNA 
or hTERT siRNA were injected subcutaneously into each flank of athymic nude mice. The tumor dimensions were measured 
every 3 days. The mean tumor volume (mm3) was calculated according to the formula: (d2 × D)/2, where d and D are the 
shortest and longest diameters of the tumor, respectively. All measurements were performed in a coded, blinded fashion. Data 
are shown as mean ± SD with 5 mice per treatment group.
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Figure 3 (see legend on next page)
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pared to the actual plasma concentration of free doxoru-
bicin, which could reach 50 μM [26]. The doxorubicin
treatment had a cytotoxicity comparable to the hTERT-
siRNA treatment, but with a somewhat slower kinetics
and did not plateau by day 4 (Fig. 2A and 2B). The FACS
analysis showed that the MCF-7 cells were equally prone
to apoptosis induction by either treatment. The MDA-MB-
453 cells seemed to have a higher resistance to doxoru-
bicin-induced apoptosis than siRNA-induced apoptosis,
although the difference did not reach statistical signifi-
cance (Fig. 3A).
The combined use of doxorubicin and hTERT-siRNA
showed a cumulative effect. The cells were first transfected
with the siRNA, and then doxorubicin was added. From
the MTT assay, already half or more than half of the cells
did not survive by the end of the first day of the treat-
ments. The decline in viable cells then followed the rate of
decline of doxorubicin treatment alone. By the end of day
4, more than twice as many cells were dead from the com-
bined treatment (Fig. 2). Both cell lines behaved similarly
towards the treatments. The FACS analysis revealed that
about 32% of the cells for both cell lines were apoptotic,
which was roughly close to the sum of the apoptotic cells
caused by hTERT siRNA and doxorubicin alone, thus
again showing an additive effect of the combined treat-
ment.
5. The breast cancer cell lines showed differential 
senescence response to doxorubicin
Telomeric dysfunctions can trigger cells to enter replica-
tive senescence [27,28], a mechanism by which tumor
cells can lose their replicative capacity by entering a termi-
nally arrested state. We therefore examined if the hTERT
siRNA transfection would induce cells to enter senescence.
We found that only about 10% of the hTERT siRNA trans-
fected cells of both cell lines were β-galactosidase positive
(Fig. 3B). Thus, our siRNA treatment most likely did not
"activate" senescence.
Doxorubicin has been known to cause cell to senesce [27-
30]. We examined the senescence of the two cell lines
under our doxorubicin treatment conditions. Interest-
ingly, we found that our two cell lines reacted differently
towards doxorubicin in terms of senescence. As expected,
MCF-7 cells showed considerable senescence (about one-
third of cells; Fig. 3B, white bars). On the other hand, only
about 10% of MDA-MB-453 cells were β-galactosidase
positive (Fig. 3B, grey bars). This was in contrast to the
similar apoptotic response of the two cell lines towards
doxorubicin. Finally, the combined treatment of hTERT
siRNA and doxorubicin also elicited a differential senes-
cence response: significantly fewer of the MDA-MB-453
cells showed senescence than did the MCF-7 cells, but
both cells lines underwent apoptosis similarly (Fig. 3A
and 3B).
Discussion
There have been consistent efforts in enhancing the effect
of doxorubicin treatment in human cancer cells through
the concerted inhibition of telomerase [19,31-33]. Our
present study investigated whether the direct addition of
hTERT siRNA as the method of telomerase inhibition
would enhance the cytotoxicity of low dose doxorubicin
on breast cancer cells. We showed that the combined
treatment of hTERT siRNA and doxorubicin indeed
caused more breast cancer cells deaths than either treat-
ment alone.
The effectiveness of siRNA inhibition is highly sequence-
dependent. We were able to find one which had a robust
effect. Unlike small molecule inhibitors of hTERT [34,35],
or methods that target the RNA component of telomerase
[36,37], where a long lag time is observed due to telomere
attrition before apoptosis from senescence can occur, the
apoptosis induction by our siRNA transfection was rela-
tively rapid. We speculated at first that the rapid response
was a result of telomere uncapping. The telomeres are
capped by telomerase and its associated proteins which
physically protect the telomeric ends. Disruption of the
cap due to the reduced hTERT level may trigger a p53-
independent, telomere-associated DNA-damage apopto-
sis [10,11]. However, Gandellini et al. [18] have shown
that the rapid inhibition by their hTERT siRNA was not
Effect of hTERT-siRNA combined with doxorubicin on apoptosis and senescence of breast cancer cell lines Figure 3 (see previous page)
Effect of hTERT-siRNA combined with doxorubicin on apoptosis and senescence of breast cancer cell lines. (A) 
Apoptosis of breast cancer cells induced by hTERT-siRNA and doxorubicin. MCF-7 and MDA-MB-453 cells were untreated 
(blank control), transfected with control or hTERT siRNA, and then treated with 0.5 μM doxorubicin. After 48 h of incubation, 
apoptotic cells were detected by FACS. Percentages of apoptotic cells are shown as mean of 3 experiments ± SD (error bar); 
*, p < 0.01; ***, p < 0.0001, two-tailed student's t-test. (B) Senescence of breast cancer cells induced by hTERT-siRNA and 
doxorubicin. MCF-7 and MDA-MB-453 cells were untreated (blank control), transfected with control or hTERT siRNA, and 
then treated with 0.5 μM doxorubicin. After 48 h of incubation, cells were stained for β-galactosidase activity. The percentage 
of β-galactosidase-positive cells was calculated by counting 3 representative fields of at least 100 cells in each group, shown as 
the mean ± SD (error bar); *, p < 0.01; **, p < 0.005; ***, p < 0.0001; ‡, p < 0.01 between cell types; ‡‡, p < 0.001 between cell 
types.BMC Cancer 2009, 9:133 http://www.biomedcentral.com/1471-2407/9/133
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due to telomere uncapping or shortening. It would be
interesting to know if the rapid apoptosis induction by
siRNA is p53 dependent, and if any of the DNA repair
pathways may be involved. Recent studies on telomerase
have also shown that telomerase is involved in DNA
repair and is a binding partner to proteins that function in
cell viability and proliferation [38,39]. Disruption of
hTERT expression thus may be impairing other vital cellu-
lar functions as well, which may be another reason for the
robustness of the hTERT siRNA in inducing apoptosis.
Our results showed a rapid apoptosis induction by both
the hTERT siRNA and doxorubicin, but a cell type depend-
ent senescence response, which is in disagreement with
published results, where doxorubicin did not induce
apoptosis, but rather senescence in MCF-7 cells [28]. Dis-
crepancies among the same cell line arisen from culture
may certainly lead to different responses, and the dose
schedule and end point selection may also explain the dif-
ferences. Our cells were continuously exposured to 0.5 μM
doxorubicin for 2–4 days, while Elmore et al.'s study [28]
exposed the cells to 1 μM doxorubicin for 2 hours, and
assayed 5 days later. It was also interesting to see our two
cell lines senesced differently towards doxorubicin. Pre-
sumably, our MDA-MB-453 cells and MCF-7 cells have
wild type p53 activity. MDA-MB-453 cells are, however,
estrogen receptor alpha negative. Further investigation
into these differences will most certainly add to our
understanding of the mechanisms controlling cell fate.
A very low dose of doxorubicin (0.5 μM) was used in our
studies. The actual plasma concentration of free doxoru-
bicin that is reached upon intravenous bolus administra-
tions into average sized persons can reach 50 μM [26]. We
are now determining if the same cumulative effect can still
be seen in a doxorubicin-resistant breast cancer cell line
and if it can be done at an even lower dose of doxorubicin
as well.
The  in vivo tumor growth experiment clearly demon-
strated impaired growth of the tumors formed by the
hTERT siRNA transfected MCF-7 cells. While admittedly
the experiment did not directly address the ability of
hTERT siRNA to induce apoptosis in pre-existing tumors,
the results nonetheless reflect the possible beneficiary
effects of siRNA therapies and validates ongoing efforts in
optimizing a siRNA delivery system into tumors. Our in
vitro results also suggested that a combination treatment
of breast cancer cells with siRNA together with doxoru-
bicin can represent a new approach of breast cancer treat-
ment. The combined treatment of hTERT siRNA and
doxorubicin almost doubled the number of apoptotic
cells than when either treatment was used alone. Our ulti-
mate goal will be to extend our in vitro findings on the
combined effects of hTERT siRNA and doxorubicin in pro-
moting breast cancer cells apoptosis in vivo. The technol-
ogy of siRNA delivery is rapidly developing. Aside from
the traditional, viral-based delivery systems [17], nanote-
chnology is also being applied [40,41]. As mentioned
before, liposomal doxorubicin is already an approved
treatment for breast cancer; albumin nanoparticulate
chaperones of paclitaxel were approved for locally recur-
rent and metastatic breast cancer in 2005 [7,42,43]. It is
foreseeable that a simultaneous delivery of doxorubicin
and siRNA may become feasible with a nanoparticle
encapsulation system.
Conclusion
The study demonstrated the potential of inhibiting telom-
erase as an effective treatment of breast cancer when used
alone and, when used in conjunction to doxorubicin,
could potentiate the cytotoxic effect of the drug to breast
cancer cells.
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